{"id":"NCT00444457","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants","officialTitle":"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2007-03-07","resultsPosted":"2010-07-14","lastUpdate":"2012-10-15"},"enrollment":1712,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent Pneumococcal Conjugate Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"7vPnC","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of the immune response, as well as for non-inferiority and safety as compared to 7-valent Pneumococcal Conjugate Vaccine.","primaryOutcome":{"measure":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series","timeFrame":"1 Month after the infant series (7 Months of age)","effectByArm":[{"arm":"13vPnC (Pilot Lot 1)","deltaMin":1.33,"sd":null},{"arm":"13vPnC (Pilot Lot 2)","deltaMin":1.34,"sd":null},{"arm":"13vPnC (Manufacturing Lot)","deltaMin":1.75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":78,"countries":["United States"]},"refs":{"pmids":["23584582","23104129"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":486},"commonTop":["Irritability","Tenderness (any)","Increased sleep","Decreased appetite","Irritability"]}}